Publications

Trend Analysis of Oritavancin and Comparator Agents’ Activities against Enterococcus species Causing Infections in US Medical Centers between 2017–2019 and 2022.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #734

Activity of Sulbactam-Durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates.  Lead author: MD Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2517

Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints. Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2801

Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021).  Lead author: Mariana Castanheira, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2756

High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019–2021).  Lead author: Lalitagauri M. Deshpande, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2139

Activity of Meropenem-Vaborbactam Tested against Burkholderia Species Isolates.  Lead author: Mariana Castanheira, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2757

Activity of Aztreonam-avibactam and Carbapenem-resistant Enterobacterales Isolates Collected in a Six-year Period (2017–2022).  Lead author: Mariana Castanheira, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2755

Antimicrobial Activity of Aztreonamavibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022).  Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2146

Frequency, Antimicrobial Susceptibility, and Molecular Characterization of Carbapenem-Resistant Enterobacterales Stratified by United States Census Divisions: Results from the INFORM Program (2018–2022).  Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2802

Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Soft Tissue Infections (SSTIs) in US Medical Centers between 2017–2019 and 2022.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #1812

Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2020–2022).  Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2598

Cefiderocol Activity Against Multidrug-resistant and Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020–2022).  Lead author: Rodrigo E. Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2174

Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Multidrug-resistant Enterobacterales Clinical Isolates From United States Hospitals (2020–2022).  Lead author: Rodrigo E. Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2172

Impact of the COVID Pandemic in Susceptibility Patterns of Gram-Positive Organisms: A Report from the SENTRY Antimicrobial Surveillance Program.  Lead Author: Cecilia G. Carvalhaes, presented at ASM Microbe, June 15-19, Houston, TX, USA

Impact of the COVID Pandemic in Susceptibility Patterns of Gram-Negative Organisms: A Report from the SENTRY Antimicrobial Surveillance Program. Lead author: Mariana Castanheira. Presented at ECCMID 2023, April 15-18, Copenhagen.

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Pneumonia in Europe and United States: Results from the SENTRY Program (2019–2021). Lead author: Helio Sader. ECCMID 2023, April 15-18, Copenhagen.

Bloodstream Infections in Europe and United States: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Helio Sader. Presented at ECCMID 2023, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against US Enterobacterales, Including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID, April 15-18, Copenhagen.

Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021) by HS Sader, RE Mendes, SJ Ryan Arends, CG Carvalhaes, D Shortridge, and M Castanheira in Int J Antimicrob Agents 2023; 61(4): 106744.

Performance of the Vitek 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales from North and Latin America by CG Carvalhaes, D Shortridge, LN Woosley, N Gurung, and M Castanheira in Microbiol Spectr 11(1): 2023, 046673-22.

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19) by Sader HS, Mendes RE, Duncan LR, Carvalhaes CG, and Castanheira M in J. Antimicrob. Chemother. 77 (2022); 2642-2649.

Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Frequency and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Patients with Bloodstream Infections in United States (US) Medical Centers (2020–2021). Lead author: Helio Sader, IDWeek 2022, October 19-23, Washington DC.

Increase in the Occurrence of Carbapenem-Resistant Enterobacterales in United States Hospitals from 2019 to 2021 and Activity of Novel β-Lactam/
β-Lactamase Inhibitor Combinations Against These Isolates. Lead author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Activity of Oritavancin and Comparator Agents Against Coagulase-Negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019). Lead author: Cecilia G Carvalhaes, IDWeek 2022, October 19-23, Washington DC.

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019) by Pfaller MA, Mendes RE, Streit JM, Carvalhaes, CG in Diagnostic Microbiology and Infectious Disease 2022; 104: 115804.

Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020) by Sader HS, Castanheira M, Carvalhaes CG, Arends SJR, Mendes RE in Microbial Drug Resistance 2022; 28 (9): 935-940.

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018 by Shortridge D, Streit J, Pfaller M, Tulloch M, Chen WT, Castanheira M in J. Glob. Antimicrob. Resist. 31 (2022): 98-103.

Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme by Carvalhaes CG, Sader HS, Streit JM, Mendes RE in JAC-Antimicrob. Resist. 4(5): 2022, dlac088

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020) by Sader, HS, Castanheira, M, Huband MD, Shortridge, D, Carvalhaes, CG, Mendes, RM in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41, 867-873.

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. By Shortridge D, Streit JM, Mendes R, and Castanheira M published in Microbiol. Spectr. 2022; 10 (2),  e02712-21.

Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Prevalence of Carbapenemases and Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Among a Global Collection of Enterobacterales. Lead author: M Castanheira, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #2164

Oritavancin Activity Against Gram-positive Isolates Responsible for Intra-Abdominal Infections in Europe and Surrounding Regions During 2015-2019. Lead author: CG Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #466

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa from Patients in ICU of US Medical Centres in 2021. Lead author: HS Sader, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Antimicrobial Susceptibility of Enterobacterales Causing Infections in Intensive Care Unit Patients: The Role of New β-Lactamase Inhibitor Combinations. Lead author: CG Carvalhaes, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #381

Dalbavancin Activity against Bacterial Isolates from Pediatric Patients: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program for the United States and Europe (2019-2021). Lead author: HS Sader presented at St Jude/PIDS Pediatric Infectious Diseases Research Conference, March 3-5, 2022. Virtual conference

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020). by Sader HS, Mendes RE, Arends SJR, Carvalhaes CG and Castanheira M. published in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41 (3): 477-487

Activity of the novel aminomethylcycline KBP-7072 and comparators against 1,057 geographically diverse recent clinical isolates from the SENTRY Surveillance Program, 2019. by Huband MD, Thompson JD, Gurung ND, Liu Q, Li L, Zhang J, Streit JM and Castanheira M. published in Antimicrob. Agents Chemother. 2022; 66 (1): e0139721

Activity of oritavancin against Gram-positive pathogens causing bloodstream infections in the United States over 10 Years: Focus on drug-resistant enterococcal subsets (2010-2019). by Carvalhaes CG, Sader HS, Streit JM, Castanheira M and Mendes RE. published in Antimicrob. Agents Chemother. 2022; 66 (2): e0166721

Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019. by Sader HS, Carvalhaes CG, Mendes RE and Castanheira M. published in Int. J. Infect. Dis. 2022; 116: 306-312

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. by Sader HS, Castanheira M, Duncan LR and Mendes RE. published in Int. J. Infect. Dis. 2021; 113: 279-281

Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018-2020). by Sader HS, Mendes RE, Streit JM, Carvalhaes CG and Castanheira M. published in Diagn. Microbiol. Infect. Dis. 2022; 102 (1): 115557

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Infective Endocarditis from the United States and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program, Lead author: HS Sader. Presented at CHEST 2021 Annual Meeting, October 17-20, Virtual and Orlando, FL
Poster #36440

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. by Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS and Castanheira M published in J. Antimicrob. Chemother. 2021; 76 (11): 2833-2838

Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents. by Sader HS, Mendes RE, Doyle TB, Davis AP and Castanheira M. JAC Antimicrob. Resist. 2021; 3 (3): dlab136

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. by Sader HS, Duncan LR, Doyle TB and Castanheira M. published in JAC Antimicrob. Resist. 2021; 3 (3): dlab126

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Five-Year Trends on the Susceptibility of Enterobacterales to Plazomicin and Other Aminoglycosides in Hospitals in the United States (2016-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference